Genomic Analysis Of Host Response To Influenza A Infection
Funder
National Health and Medical Research Council
Funding Amount
$168,530.00
Summary
Influenza virus infects millions of people globally. However, it remains poorly understood why some infected individuals succumb to life threatening complications whilst others recovered relatively unaffected. This study use advance molecular technique to study influenza infection. It aims to identify the key steps in our immune systems that are progressively disrupted during influenza infection and how this process lead to a break down in our natural defence against the virus.
The Molecular Physiology Of Streptococcus Pneumoniae During Sepsis
Funder
National Health and Medical Research Council
Funding Amount
$232,504.00
Summary
The project will determine the way in which pneumococcus changes its properties when it invades the bloodstream of the human host. Since these changes are linked to sepsis then this new understanding will provide information that can be used to manage and control acute pneumococcal infection.
Malaria And Infectious Diseases In The Asia-Pacific: Drugs, Vaccines And Diagnostics
Funder
National Health and Medical Research Council
Funding Amount
$210,873.00
Summary
Dr Karunajeewa is an expert in the treatment of malaria and other infectious diseases that have a major impact on the health of people living in developing countries of the tropical zone of the Asia-Pacific region. His ongoing research aims to develop better ways of diagnosing these infections, defining their relative importance in terms of overall burden of disease, finding optimal drug treatments and testing the effectiveness of new vaccines for their prevention.
Improving Outcomes Of Severe Bacterial Infections In Northern Australia
Funder
National Health and Medical Research Council
Funding Amount
$217,274.00
Summary
Severe infections such as pneumonia can cause failure of vital organs (severe sepsis) and subsequent death. 30-40% of people who develop severe sepsis die, even with the best modern therapies. Sepsis is five times more common in northern Australia than elsewhere. In this program of research, we plan to test new therapies for sepsis; to determine the causes of and risk factors for severe pneumonia in northern Australia; and to use this information to inform new guidelines for the management of se ....Severe infections such as pneumonia can cause failure of vital organs (severe sepsis) and subsequent death. 30-40% of people who develop severe sepsis die, even with the best modern therapies. Sepsis is five times more common in northern Australia than elsewhere. In this program of research, we plan to test new therapies for sepsis; to determine the causes of and risk factors for severe pneumonia in northern Australia; and to use this information to inform new guidelines for the management of sepsis and pneumonia in northern Australia.Read moreRead less
Pathophysiology And Treatment Of Malaria And Other Tropical Infectious Diseases Prevalent In Our Region
Funder
National Health and Medical Research Council
Funding Amount
$560,284.00
Summary
Nick Anstey is internationally recognised for his discoveries in malaria and other tropical infectious diseases. He leads a major tropical infectious disease research program in Darwin and SouthEast Asia that attracts some of the brightest researchers and students from Australia and beyond to understand disease mechanisms and work on new ways to treat illness and prevent death. He uses results to change policy and practice not only in Australia but around the world.
A Study To Investigate Alternative Regimens For Pneumococcal Vaccination Of Infants In A Developing Country
Funder
National Health and Medical Research Council
Funding Amount
$1,622,210.00
Summary
Streptococcus pneumoniae (Pnc) is the leading vaccine preventable cause of serious infection in infants. The current Pnc conjugate vaccine is very expensive (approximately USD $200-infant) so it is unlikely to be affordable for most developing countries. Moreover, as health care access in developing countries may be episodic and unreliable, many children do not receive either complete or timely vaccine courses. Therefore, it is important to investigate affordable and flexible ways to deliver thi ....Streptococcus pneumoniae (Pnc) is the leading vaccine preventable cause of serious infection in infants. The current Pnc conjugate vaccine is very expensive (approximately USD $200-infant) so it is unlikely to be affordable for most developing countries. Moreover, as health care access in developing countries may be episodic and unreliable, many children do not receive either complete or timely vaccine courses. Therefore, it is important to investigate affordable and flexible ways to deliver this vaccine, which are safe and effective. A recent WHO-GAVI meeting to address impediments to the introduction of these vaccines in developing countries recognized the need to evaluate other regimens of Pnc conjugate vaccine as an important research priority. This study has been deliberately formulated with that need in mind. The site for this research is Fiji. Although health services are good, Pnc disease, particularly pneumonia, remains the commonest cause of childhood morbidity and mortality. Fiji has good vaccine coverage and was the first Pacific country to introduce Hib vaccine. The arrival of the new, expensive Pnc conjugate vaccine presents a dilemma for Fiji and many similar countries. The expense of this vaccine would consume a large portion of the health budget. This study has two components: 1. A Phase 2 immunogenicity study (involving 750 infants) to evaluate regimens using reduced numbers of doses of Pnc conjugate vaccine, and using timing of dosing and combinations with the Pnc polysaccharide (PS) vaccine that may be more suited to the epidemiology of Pnc disease in developing countries. 2. An epidemiological study will measure the burden of invasive Pnc disease and pneumonia in Fiji. This will be part of a global effort to address these issues, and will be used to develop rapid assessment tools for these diseases in developing countries. We will seek cofounding for this component.Read moreRead less
Characterisation Of Extracellular DNases Of Pseudomonas Aeruginosa And Their Contribution To Disease
Funder
National Health and Medical Research Council
Funding Amount
$418,516.00
Summary
The bacterium Pseudomonas aeruginosa causes a number of serious diseases of humans particularly of immunocompromised patients. We have found that this bacterium secretes enzymes that have the ability to digest DNA. This proposal aims to work out how this bacterium uses these enzymes to infect human tissues and escape killing by immune cells. The results from this study will help to determine if these proteins may be used as targets for the development of new anti-infective drugs.
Adapting Pandemic Influenza Interventions And Management To The Newly-emerged Virus
Funder
National Health and Medical Research Council
Funding Amount
$245,098.00
Summary
The Australian Health Management Plan for Pandemic Influenza is based on data from past and current influenza. A newly-emerged influenza strain is likely to differ in some respects. This project will develop practical ways to adapt the management plan to the emerged virus from early pandemic data. It will determine the data needed to do this efficiently, to ensure that Australia receives the greatest benefit from its antiviral drugs, vaccines and other public health interventions introduced.